-
1
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Published 2023“…American Society of Hematology…”
Journal article -
2
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Published 2017“…American Society of Hematology…”
Journal article -
3
Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb...
Published 2016“…American Society of Hematology…”
Conference item -
4
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Published 2020“…American Society of Hematology…”
Journal article -
5
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
Published 2017“…American Society of Hematology…”
Journal article -
6
Results of a phase 2 trial of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukemia (CMML) - the UK monocle study
Published 2018“…American Society of Hematology…”
Conference item